Ondansetron Aurobindo

Ondansetron, the active ingredient in Ondansetron Aurobindo, is a selective 5‑HT₃ receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a serotonin (5‑HT₃) receptor antagonist indicated for several nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the incidence of nausea during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the frequency of nausea and vomiting after surgical procedures. - Pregnancy‑related nausea (hyperemesis gravidarum): used when other treatments are ineffective, under specialist supervision. - Gastroenteritis‑related nausea: alleviates nausea associated with acute gastroenteritis.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensations. - Injection site pain (if administered intravenously).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with IV use. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic drugs. - Hepatic dysfunction: elevated liver enzymes. - Severe hypotension: sudden drop in blood pressure. - Neuroleptic malignant‑like syndrome: extremely rare neurological emergency.

When using Ondansetron, consider the following safety measures:

- Cardiac monitoring: assess baseline ECG in patients with known heart rhythm disorders. - Drug interactions: review concomitant medications that may affect QT interval. - Pregnancy: use only if clearly needed; discuss risks with a healthcare provider. - Lactation: evaluate benefits versus potential infant exposure. - Renal/hepatic impairment: dose adjustment may be required; monitor organ function. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, affecting its safety profile.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Other serotonergic drugs (e.g., SSRIs, MAOIs, tramadol): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., codeine, metoprolol): ondansetron can modestly affect their metabolism. - Diuretics (e.g., furosemide): may enhance hypotensive effects. - Anticholinergic agents: may reduce the anti‑emetic efficacy of ondaconf.